Coya Therapeutics recently announced that the US Food and Drug Administration (FDA) has granted Fast Track Designation for COYA 302, a proprietary investigational biologic combination therapy with a dual mechanism of action, for the treatment of Amyotrophic Lateral Sclerosis (ALS).

The FDA Fast Track Designation is a program designed to facilitate and expedite the development and review of drugs and biologics intended to treat serious or life-threatening conditions. Its primary purpose is to ensure that promising new therapies reach patients as quickly as possible through several key regulatory advantages, which include more frequent FDA interactions, potential for rolling review, and eligibility for expedited programs such as Accelerated Approval and Priority Review.

Arun Swaminathan, PhD, Chief Executive Officer (CEO), Coya Therapeutics, “We are pleased to announce that COYA 302 has received FDA Fast Track designation for the treatment of ALS. This recognition underscores the devastating nature of ALS and the urgent need for new therapies. At Coya, we remain fully committed to advancing our lead biologic candidate, COYA 302, through the regulatory process with the ultimate goal of delivering—pending FDA approval—a safe and effective treatment for patients living with ALS and their families.”